Allison Leonard 
Allison joined the group in July 2017 and is a coop student from Northeastern University.  Allison is focused on developing new SAR for the EAAT2 project for AD and ALS.
Greg Ahn 

Greg recently graduated from Cornell University and joined the group in September 2017, as a research scientist.  Greg will be working on the synthesis of novel molecules as potential treatments for a number of neurodegenerative diseases.  In the future, Greg also plans to pursue a career in medicine.

Matthew Monte 
Matthew joined the group in July 2017 and is a coop student from Northeastern University.  Matthew is making new analogs and new SAR for the HIF2a inhibitor project. 
​Dawid Fiejtek

Dawid originally joined the group in January 2017, as a coop student from Northeastern University. Dawid worked on the synthesis of analogs in our SMA series that increases transcription of the survival motor neuron protein for the treatment of Spinal Muscular Atrophy.  Dawid is also developing water soluble pro-drugs of a poorly soluble drug that we are re-purposing for AD. Dawid is currently doing undergraduate research in the lab.  In the future, he plans to attend medical school.

Lisa Montagnon
Lisa joined the group in September 2017.  She is an undergraduate chemistry student from Bath University UK. Lisa is synthesizing new heterocycles for the EAAT2 project for the treatment of AD and ALS. 
Hamilton Coulter 
​Hamilton joined the group in September 2017 and is an chemist from Bath University UK. Hamilton is working on the synthesis of different heterocycles that modulate the activity of the innate immune system in the CNS for the treatment of neurodegenerative diseases.  

Dr. Kevin Hodgetts

Director of ​The Laboratory for Drug Discovery in Neurodegeneration

65 Landsdowne Street 

Cambridge, Massachusetts 02139

U.S.A.


Telephone: 617-768-8640 

Email:  khodgetts@bwh.harvard.edu

 

Contact

Medicinal Chemistry 2016-2017

Dr. Kevin Hodgetts is the Director of LDDN and Head of Medicinal Chemistry.

Kevin has a broad background in organic and medicinal chemistry, with experience in both industrial and academic drug discovery. Kevin spent over 15 years of experience working on treatments for diseases of the central nervous system.  Compounds from two projects that he was involved in have entered clinical trials. Kevin joined the LDDN in September 2012, to work with the academic community to design new and innovative strategies for drug discovery for neurodegenerative diseases. Kevin is Assistant Professor of Neurology at Brigham and Women's Hospital and Harvard Medical School. He also co-founded Klogene Therapeutics with Professor Carmela Abraham.

Lin Lin

Lin Lin originally joined the group in January 2015, as a coop student from Northeastern University. Lin developed the SAR on the SOD1 and CMT projects. After graduating from Northeastern, Lin is now back at the LDDN and making key contributions to the EAAT2 and HIF projects.  In the future, Lin plans to attend medical school.